AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,338,000 | -62.8% | 141,326 | -54.6% | 0.00% | -50.0% |
| Q4 2021 | $3,593,000 | +24.0% | 311,097 | +2.5% | 0.00% | 0.0% |
| Q3 2021 | $2,898,000 | -5.9% | 303,410 | -5.0% | 0.00% | 0.0% |
| Q2 2021 | $3,079,000 | +6.7% | 319,401 | +9.3% | 0.00% | 0.0% |
| Q1 2021 | $2,886,000 | -64.4% | 292,129 | -16.9% | 0.00% | -60.0% |
| Q4 2020 | $8,117,000 | +146.7% | 351,549 | +50.9% | 0.01% | +150.0% |
| Q3 2020 | $3,290,000 | +1.7% | 233,026 | +8.6% | 0.00% | 0.0% |
| Q2 2020 | $3,236,000 | +81.7% | 214,567 | +11.3% | 0.00% | 0.0% |
| Q1 2020 | $1,781,000 | +12.2% | 192,799 | +18.3% | 0.00% | +100.0% |
| Q4 2019 | $1,587,000 | +106.6% | 162,919 | +70.2% | 0.00% | 0.0% |
| Q3 2019 | $768,000 | -14.1% | 95,715 | +33.6% | 0.00% | 0.0% |
| Q2 2019 | $894,000 | -26.0% | 71,667 | -19.3% | 0.00% | 0.0% |
| Q1 2019 | $1,208,000 | +43.1% | 88,811 | +0.8% | 0.00% | 0.0% |
| Q4 2018 | $844,000 | -13.0% | 88,101 | +9.8% | 0.00% | 0.0% |
| Q3 2018 | $970,000 | -32.4% | 80,245 | -12.6% | 0.00% | 0.0% |
| Q2 2018 | $1,434,000 | +10.2% | 91,821 | +6.1% | 0.00% | 0.0% |
| Q1 2018 | $1,301,000 | +18.7% | 86,530 | +13.6% | 0.00% | 0.0% |
| Q4 2017 | $1,096,000 | -0.4% | 76,189 | +4.5% | 0.00% | 0.0% |
| Q3 2017 | $1,100,000 | +290.1% | 72,923 | +160.4% | 0.00% | – |
| Q2 2017 | $282,000 | +41.0% | 27,999 | -30.4% | 0.00% | – |
| Q4 2016 | $200,000 | -49.2% | 40,245 | -24.4% | 0.00% | -100.0% |
| Q3 2016 | $394,000 | -73.8% | 53,203 | -70.1% | 0.00% | -50.0% |
| Q1 2016 | $1,502,000 | +211.6% | 177,701 | +257.7% | 0.00% | +100.0% |
| Q4 2015 | $482,000 | -8.9% | 49,676 | +31.3% | 0.00% | 0.0% |
| Q3 2015 | $529,000 | +15.0% | 37,832 | +16.3% | 0.00% | 0.0% |
| Q2 2015 | $460,000 | +1603.7% | 32,519 | +153.8% | 0.00% | – |
| Q1 2014 | $27,000 | -10.0% | 12,813 | +0.9% | 0.00% | – |
| Q4 2013 | $30,000 | – | 12,702 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |